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Abstract  
Background: Drug utilisation studies from paediatric hospitals that do not have access to patient level data on medication use are 
limited by a lack of standardised units of measures that reflect the varying daily dosage requirements among patients. The World 
Health Organization’s defined daily dose is frequently used in adult hospitals for benchmarking and longitudinal analysis but is not 
endorsed for use in paediatric populations. 
Objective: Explore agreement between standard adult-based defined daily doses (DDD) and paediatric estimates of daily injectable 
antibiotic use in a Paediatric Intensive Care Unit that does not have access to individual patient-level data.  
Methods: Hospital pharmacy antibiotic use reports and age-specific occupied bed-day data from 1 January 2010 to 31 May 2016 were 
extracted. Paediatric reference dosages and frequencies for antibiotics were defined and applied to three paediatric units of measure. 
Measures were applied to extracted data, agreement between antibiotic use measured in the adult DDD and each of the paediatric 
measures was assessed visually via Bland-Altman plots and linear regression for each antibiotic. 
Results: Thirty one different antibiotics were used throughout the study period. Despite varying daily dosages in grams, the daily use of 
vials was unchanged from birth to 18 years for thirteen antibiotics. Agreement between DDD and vial-based measures was closer than 
the total recommended daily dose that did not account for wastage during preparation and administration. Vial-based measures were 
unaffected by vial size changes due to drug shortage. 
Conclusions: Agreement between the DDD and vial-based measures of use supports the use of DDD for select antibiotics that may be 
targeted by antimicrobial stewardship programs. Vial based measures should be further explored in hospitals with single vial policies; 
detailed understanding of hospital practice is needed before inter-hospital comparisons are made. 
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INTRODUCTION 
Monitoring hospital antimicrobial use and resistance is key 
to antimicrobial stewardship (AMS) efforts to curtail the 
rise of antimicrobial resistance. AMS programs monitor 
compliance with interventions that aim to optimise therapy 
and identify utilisation patterns that warrant further 
investigation. In many countries hospital-level data also 
contribute to large-scale surveillance programs that enable 
benchmarking and epidemiological research.1   
In the absence of patient-level data (typically from 
electronic prescribing or medication administration 
systems) to capture actual days of therapy (DOT) and 
prescribed daily doses, antimicrobial use in adult hospitals 
is frequently sourced from pharmacy information systems 
and reported using the defined daily dose (DDD). These 
numerators are standardised by a measure of activity 
(denominator) such as patient days or admissions. The 
World Health Organization’s DDD is considered a technical 
unit of measure based on the average daily dose of each 
agent for its most common indication in an adult. As the 
DDD is a fixed value, it cannot account for variations 
attributed to individual patient requirements such as 
indication, age or weight-based dosing or dose adjustment 
for comorbidities such as renal impairment.2 For this 
reason, DDD is not validated or endorsed for use in 
paediatric populations where individualised prescribing is 
commonplace.3 As a consequence, hospital utilisation data 
for paediatric patients may be excluded from larger 
antimicrobial surveillance programs that rely on DDD to 
monitor use in hospitals and the community.1,4 
Despite these limitations, AMS programs in children’s 
hospitals without access to patient level records are 
expected to monitor antimicrobial usage patterns, and 
demonstrate cost-effective antimicrobial therapy.5,6 
Surveys of actual prescribing, though ideal, are resource 
intensive in the absence of electronic systems and may not 
be feasible for routine surveillance. Therefore, pharmacy 
information systems continue to be used for antimicrobial 
utilisation using measures such as drug costs, DDD and 
paediatric defined daily doses.7 
In the absence of any endorsed paediatric measure for 
hospitals without access to patient level data, The WHO 
recommend prescribed doses and indications are 
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compared to DDD values.2 However, the relationship 
between prescribing and reported use from pharmacy 
information systems is further complicated by the amount 
of drug discarded in the process of preparing individualised 
doses from standard sized vials.3,8 
This study explored the levels of agreement between adult 
DDD and feasible paediatric estimates of daily antibiotic 
use (numerators) in the context of a paediatric hospital that 




This retrospective study was conducted in a 170-bed 
university affiliated tertiary paediatric hospital in New 
South Wales, Australia. The hospital is adjoined by two 
public hospitals for general adult and specialist women’s 
and newborn care. A range of services are shared across 
the campus including operating theatres, radiology and 
pharmacy. The hospital’s level six paediatric intensive care 
unit (PICU) accepts complex surgical and oncology patients 
from birth to 18 years, including preterm neonates 
transferred from the neonatal intensive care unit (NICU) at 
the adjoining hospital. 
Nursing staff order routinely prescribed antimicrobials that 
have been approved as “imprest” items from a pharmacy 
warehouse shared between the adult and paediatric 
hospitals. Pharmacy warehouse staff distribute imprest 
items to individual wards with limited or no direct contact 
with pharmacists; non-imprest antimicrobials are dispensed 
as whole vials to individual patients by pharmacists in the 
hospital dispensary. Pharmacists review and endorse both 
imprest and non-imprest medications prescribed by 
doctors on paper-based medication charts but do not 
collect data on the patients or medications reviewed. 
Due to these ordering methods antimicrobial use is not 
consistently linked to individual patients. All injectable 
medications, other than those associated with high cost or 
special handling requirements, are prepared by nurses on 
the ward from whole vials. State-wide infection control and 
medication handling policies mandate the use of single 
dose vials over multi-dose products and require nurses to 
discard any unused portions of injectable medicine.9 
Data collection and analysis 
Antimicrobial and patient demographic data  
Records of antimicrobial supply to PICU inpatients from 1 
January 2010 to 31 May 2016 were extracted from the 
hospital pharmacy information system (iPharmacy, CSC, 
Sydney Australia). In keeping with the National 
Antimicrobial Utilisation and Surveillance Program methods 
used for adult hospitals in Australia, the data combined 
records of imprest distribution from the pharmacy 
warehouse and individual inpatient dispensing by 
pharmacists.4 Discharge and outpatient dispensing 
associated with the PICU cost centre code were excluded. 
WHO Collaboration Centre for Drug Statistics Methodology 
Anatomical Therapeutic Chemical (ATC) classification 
system for antimicrobials category J01, and J04 injectables 
were extracted.10 
Tobramycin and colistin for injection and inhalation could 
not be differentiated consistently throughout the study 
period and were excluded from further analysis. Injectable 
erythromycin was also excluded because it is more 
commonly prescribed for gastric motility in our institution. 
Gentamicin was excluded due to a transition from 8 hourly 
to once daily gentamicin for neonates and oncology 
patients during the study period, sporadic supply of two 
vial sizes to the PICU via imprest.  
Data entry errors were corrected after confirmation from 
pharmacy and warehouse managers; records of unused 
items returned to stock after initial supply were subtracted 
from the original month of supply. Antibiotic use for each 
agent was reported as monthly vial counts according to vial 
size in grams. Date of birth and occupied bed-day (OBD) 
data were obtained from the hospital performance unit. 
Patient age (in months) was calculated for each patient at 
each day of their PICU admission and used to create a 
database of monthly age-specific PICU occupied bed-days.  
Measures of antibiotic use 
Three paediatric measures of daily antibiotic consumption 
were derived from the dosage and frequency 
recommendations published in the national paediatric 
medication reference text and the New South Wales 
Neonatal Medicines Formulary.11,12 Where there were no 
local or national recommendations these were obtained 
from Lexi-Comp® via UpToDate and the British National 
Formulary for Children.13,14 For consistency across 
measures reference dosages and frequencies were defined. 
Where possible, the reference dosage in milligram per 
kilogram and reference frequency were roughly equivalent 
to the adult values assigned by WHO. For example, DDD 
assignments for J01CR beta-lactams with beta-lactamase 
inhibitors (piperacillin-tazobactam and ticarcillin-
clavulanate) were an average of two commonly prescribed 
dosage schedules, therefore, the same approach was 
taken. Where the DDD assignment reflected maintenance 
or severe infection, the same principle was applied to the 
reference dosage and frequency. Patient gender and actual 
weight was not available, therefore, the median weight for 
age (in months) was obtained from the United States 
Centers for Disease Control and Prevention weight-for-age 
percentile reference ranges for girls.15 
Paediatric measure 1: Estimated daily use of vials  
The estimated daily use of vials was a fixed value equal to 
the reference frequency children. A single vial was assigned 
to each dosage administration within 24-hours without 
modification for patient weight, age, dosage delivered, or 
vial size supplied. For example, the estimated use of vials 
for vancomycin was fixed at four  vials per day despite the 
fact that some patients would require more than a single 
vial for each dosage administration due to age, weight or 
the prescribed dose. 
Paediatric measure 2: Age-adjusted daily use of vials  
Age-specific dosage and frequency, potential residual 
antibiotic and age-specific occupancy in PICU (age-specific 
occupied bed days) were incorporated into the age-
adjusted daily use of vials. First, individual dosages were 
calculated for each antibiotic for ages 3 months to 18 years 
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(reference dosage in mg/kg x 50th percentile weight-for-
age, up to the maximum reference dosage). The number of 
whole vials required to administer the calculated dosage 
was assigned according to the vial sizes supplied to PICU; 
dosages were allowed to be rounded down to the nearest 
whole number of vials where the dosage delivered would 
remain within 5% of the calculated dosage. Average daily 
vial requirements were obtained by multiplying the number 
of whole vials required per dosage administration by the 
reference frequency. Average daily vial requirements for 
neonates broadly accounted for gestational age by taking 
the lowest or most commonly used frequency in neonates. 
Unless otherwise stated, gestational and postnatal age-
adjustment was applied uniformly to all patients under 3 
months old to account for possible preterm birth.  
The age-adjusted daily use of vials was calculated for each 
month of the study period, by applying the proportion of 
age-specific PICU occupied bed days to the corresponding 
average daily vial requirements for each age. i.e., Age-
adjusted daily use of vials= ∑ (Average daily vial 
requirement for age × Proportion of occupied bed-days for 
age).  
Neonatal dosage adjustments were not performed for 
antibiotics that were deemed rare or unsuitable for 
neonatal use. The proportion of age-specific occupied bed-
days was recalculated accordingly. 
Paediatric measure 3: Recommended daily dose (RDD)  
The median PICU admission age each month was used to 
select the age-specific reference dosage (mg/kg), reference 
frequency and 50th percentile weight used to calculate the 
monthly RDD unit of measure i.e., RDD = (Reference dosage 
in milligram per kilogram × reference frequency) × 50th 
percentile weight for age.  
PICU antibiotic use  
Monthly use of each agent in PICU was reported as the 
number of WHO ATC DDDs ([vial count × vial size]/ ATC 
DDD 2016); the number of estimated daily use of vials (vial 
count/Estimated daily use of vials); the number of age-
adjusted daily vials (vial count /Age-adjusted daily use of 
vials and the number of RDDs ([vial count × vial size]/ RDD). 
Notably, PICU antibiotic use in measured in RDDs and age-
adjusted daily use of vials were obtained by dividing 
monthly use by the age-adjusted daily use of vials or RDD 
unit of measure for the month in question.  
Ethics  
Ethics approval was granted by the hospital Human 
Research Ethics Committee (LNR/16/SCHN/445) and 
ratified by the University of Technology Sydney. 
Statistical analysis 
Data was extracted to a Microsoft Excel 2016 database 
(Microsoft Corporation, Redmond, WA, USA) for initial 
calculations. Statistical analysis was performed in R version 
3.3.1 (R Foundation for Statistical Computing, Vienna, 
Austria). 
Descriptive statistics were used to report the monthly age-
adjusted estimated daily use of vials measure that resulted 
from the PICU patient population throughout the study 
period. Agreement between the DDD and the estimated 
daily use of vials, the DDD and the age-adjusted daily use of 
vials, and the DDD and the RDD was assessed visually via 
Bland-Altman plots for each antibiotic with at least 10 
months of use in the PICU (10 observations).  
Differences in estimated monthly use between DDD and 
each of the paediatric use measures were plotted against 
the Averages of the two measures, i.e. y = Differences = use 
in DDD – use in paediatric measure, x=Averages = (use in 
DDD + use in paediatric measure)/2. Shapiro-Wilk tests and 
visual inspection of Bland-Altman and quantile-quantile 
plots confirmed whether the calculated differences were 
normally distributed. Where the assumption of normality 
was not met linear regression was used to describe the 
mean difference as a function of Averages. As described by 
Bland and Altman, the mean differences are obtained from 
a fitted regression model (model 1), B0 + B1Averages = 
Differences. The limits of agreement are then derived from 
a second linear regression model, C0 + C1Averages = 
Residuals, where the residuals are the absolute residuals 
from model 1. Statistical significance was determined by 
the p-value of the coefficients of the Averages, Β1 and C1. 
The limits of agreement were calculated as ± 2.46 (C0 + 
C1Averages) of the mean difference (B0 + B1Averages).16 
Where distributions varied between antibiotics the most 
common distribution determined the method of analysis, 
and a single approach was applied to antibiotics. All tests 




Monthly OBD in the PICU ranged from 228 in January 2010 
to 510 in July 2013 (mean=388, SD=64). Median PICU 
admission age was 16 months (IQR 3 months – 6 years 6 
months). Of the 30 different injectable antibiotics supplied 
to the PICU throughout the study period, 60% (18/30) were 
supplied in one vial size. Cefotaxime was the only antibiotic 
supplied in more than two sizes. A reference dosage and 
frequency was assigned for all the included antibiotics.  
For 12 antibiotics that were limited to a single vial size, the 
estimated daily use of vials was equal to adult DDD in terms 
of the reported grams of use, and the number of vials 
required (Online appendix: Table 1). These were; 
azithromycin, cefalotin, cefazolin, imipenem, lincomycin, 
metronidazole, moxifloxacin, piperacillin-tazobactam, 
rifampicin, teicoplanin, ticarcillin-clavulanate and 
tigecycline. Whilst amikacin, aztreonam, cefoxitin, linezolid, 
daptomycin, trimethoprim-sulfamethoxazole were also 
supplied in a single size the estimated daily use of vials was 
not equal to DDD (Online appendix: Table 1). For eight 
antibiotics the measure accounted for the average daily vial 
requirements in all patients after the neonatal period, 
despite 2-fold or greater variation if reported as DDD 
(ampicillin, cefepime or flucloxacillin = 1.0–2.0 DDD, 
meropenem and ceftazidime = 0.75–1.5 DDD, clindamycin = 
0.5–1.0 DDD, benzylpenicillin ~0.67–1.33 DDD, cefotaxime 
= 0.5–2.0 DDD). 
Almost half of the included agents (14/30) had an 
estimated daily use in vials that accounted for average daily 
vial requirements for all patients, regardless of age-
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Figure 1. Age-adjusted estimated daily vials unit of measure generated from age-specific occupied bed-days in the 
Paediatric Intensive Care Unit. (values reported in Online appendix: Table 1). 
occupied bed days assigned to neonatal and older children 
(Online appendix: Table 1). Neonatal daily vial 
requirements varied from the reference frequency for 
children (i.e., estimated daily use of vials) for nine agents, 
(ampicillin, benzylpenicillin, cefazolin, cefotaxime, 
ceftazidime, flucloxacillin, metronidazole, ticarcillin-
clavulanic acid and vancomycin). Calculated average daily 
vial requirements for age identified antibiotics that 
required changes to the estimated daily use of vials to 
account for weight or age in children (cefoxitin, ceftriaxone, 
aztreonam, trimethoprim-sulfamethoxazole, amikacin, 
ciprofloxacin, vancomycin, linezolid).  
The age-adjusted daily use of vials for vancomycin (Figure 
1) varied more than any other agent due to differing 
average daily vial requirements in both neonates and 
children (range 3.3–5.0 vials), followed by cefoxitin (range 
3.3–4.6 vials) and trimethoprim/sulfamethoxazole (range 
2.3–3.2 vials). 
Agreement between reported use in DDD and the 
paediatric units of measure was completed for the 20 
antibiotics that were supplied to the PICU during 10 or 
more months of the 77 month study period. Shapiro-Wilk 
tests of the differences confirmed normal distributions for 
only two antibiotics and thus regression methods were 
used to determine the mean difference and limits of 
agreement. Bland-Altman plots of PICU use in DDD and 
estimated daily use of vials showed perfect agreement for 
azithromycin, cefalotin, cefazolin, lincomycin, 
metronidazole, piperacillin-tazobactam and ticarcillin-
clavulanic acid (7/20). 
The relationship between the differences between DDDs 
and estimated daily use of vials used in PICU versus their 
averages was perfectly linear for amikacin, trimethoprim–
sulfamethoxazole and linezolid, as these were all limited to 
a single vial size there was no deviation from the regression 
lines (Figure 2). The mean difference for vancomycin in 
DDD and estimated daily use of vials was not statistically 
significant (p=0.059), with only three deviations attributed 
to months during which a small number of larger sized 
vancomycin vials were supplied.  
As expected, agreement varied for antibiotics that were 
supplied in multiple vial sizes. Flucloxacillin plots exhibited 
the narrowest limits of agreement, and the most 
prominent slope (Figure 2). The steep incline suggested 
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that higher usage months measured in DDD may vastly 
overestimate days of use compared to estimated daily use 
of vials. Bland-Altman plots for ampicillin produced wider 
limits of agreement as various vial sizes were more 
consistently used, including lower usage months. One in 
every four months of cefotaxime use were in perfect 
agreement (19/76, difference=0) without a statistically 
significant change in the mean difference in relation to the 
averages (p=0.922). Differences between cefotaxime use in 
DDD and estimated daily use of vials were both negative 
and positive, suggesting DDD measures could potentially 
under- and over-report use. The largest negative difference 
and most extreme positive outlier occurred during periods 
of high cefotaxime use, the former when large quantities of 
predominantly small vials were supplied (difference= -
43.73, 67% vials 0.5g), the latter when larger vial sizes were 
supplied difference = +72.5, 100% of vials 2g) (Figure 2). 
After adjustment for daily vial requirements and age-
specific OBD, metronidazole, cefazolin and ticarcillin–
clavulanate were no longer in perfect agreement (Figure 3). 
However, the impact on the differences remained small 
(Online appendix: Table 2). Differences between use in DDD 
and age-adjusted daily use of vials for ampicillin and 
flucloxacillin remained statistically significant, and positive 
in relation to the averages. Despite changes in the 
appearance of the cefotaxime and vancomycin plots, the 
mean differences were not statistically significant (Online 
appendix: Table 2); the limits of agreement were, however, 
narrower and wider respectively as expected. The 
magnitude of the mean difference in relation to the 
averages changed significantly after age adjustment to 
benzylpenicillin and ciprofloxacin as demonstrated by the 
changes to the slopes (Figure 2 and Figure 3).  
Figure 2. Bland-Altman plots of World Health Organization defined daily doses and Estimated daily use of vials. 
Mean difference (solid line) and limits of agreement (broken lines) obtained from linear regression (Online appendix Table 2, 
DDD vs Estimated daily use of  vials). 
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Agreement between DDD and total recommended daily 
doses was poor. Visual inspection of Bland-Altman plots 
and linear regression showed obvious discrepancy between 
use in DDD and RDD, the relationship between the 
differences and the averages of the two measures was 
statistically significant and inversely proportional (Figure 4). 
Differences between DDD and RDD increased dramatically 
with higher average use; negative differences indicated 
that the estimated days of antibiotic use measured in RDD 
far exceeded that which was reported in DDD. 
 
DISCUSSION 
Despite its exploratory nature, this study offers some 
insight into a range of patient and organisational factors 
such as pharmacy distribution systems, single-vial policies 
and external factors such as drug shortages that influence 
the approach to antimicrobial surveillance in children’s 
hospitals. Extracted records of use together with 
medication reference texts identified a range of antibiotics 
that are likely to be reliably reported in children and 
teenagers in DDD without any adjustment, and with only 
minor adjustment in neonates. This list of agents includes 
10 that are restricted or highly restricted agents in our 
hospital. Also included is injectable metronidazole, which, 
while unrestricted, is a potential target for antimicrobial 
stewardship activities that promote IV to oral switch or 
reduce therapeutic duplication. Approximately half of the 
antibiotics used in PICU required estimated daily use of 
vials measure to be adjusted for age and weight and only 
one antibiotic, vancomycin, required adjustment for both 
neonates and children. 
Bland-Altman plots of antibiotic use measured agreement 
between each of the paediatric antibiotic use measures and 
DDD, illustrating how vial size, age and waste may impact 
drug usage reports from pharmacy supply records. 
Figure 3. Bland-Altman plots of World Health Organization defined daily doses and Age-adjusted estimated daily use of vials. 
Mean difference (solid line) and limits of agreement (broken lines) obtained from linear regression (Online appendix Table 2, 
DDD vs Age-adjusted estimated daily vials). 
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Compared to DDD, the vial-based units of measure 
appeared more robust against cefotaxime formulary 
change and drug shortage by focusing on the dosage 
frequency, rather than the actual dose. In contrast, 
agreement between PICU use measured in DDD and RDD 
suggested RDD would report considerably higher estimates 
of monthly use, even where all other measures were equal 
or similar. 
To the best of the author’s knowledge, previous weight-
adjusted methods using pharmacy data have largely 
focused on the dosage prescribed reporting use in RDD or 
proportions of DDD rather than vial requirements.
3,8,17,18
 
For example, Liem et al. suggest that “neonatal DDD” for 
ampicillin could be one tenth of the adult DDD values.3 
Applying the single vial policies in the study hospital would 
result in a reported daily use of 1g (2 vials) to 4 g (4 vials) of 
ampicillin depending on gestational and postnatal age. 
Others have argued against weight-based adjustments due 
to the broad range of paediatric doses and the wide range 
of indications, choosing to use DDD for benchmarking and 
trend analysis.19 Whilst DDD generally appeared to be 
closer to the minimum quantity reported for a single day of 
use in this setting, these conclusions may not be 
generalisable to hospitals without single vial policies, and 
different vial sizes in use. These variations are likely to limit 
the capacity for benchmarking between hospitals and 
comparisons with published surveillance reports 
internationally. 
This study has a number of other limitations. The measures 
developed in this study were modelled similar to DDD and 
share some of the same limitations, including that they 
might be based on recommended dosages that do not 
accurately reflect the most common dosage regimens 
actually used in hospitals. Prescribers may choose alternate 
regimens within the medication reference range for 
convenience (i.e., to limit the number of daily dosages), 
Figure 4. Bland-Altman plots of World Health Organization defined daily doses and  Recommended daily doses. 
Mean difference (solid line) and limits of agreement (broken lines) obtained from linear regression (Online appendix Table 2, 
DDD vs Recommended daily doses). 
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severity of infection or presence of comorbidities (e.g., 
renal impairment). However, these concerns are not 
limited to vial-based measures or children and are likely to 
be present in adult hospitals that use DDD. Vial-based 
measures may not identify a shift to higher dosages in 
milligram per kilogram that do not change the daily vial 
requirements and may overestimate use when multiple 
smaller vials are used to deliver a dose that could have 
been administered with a single vial. Furthermore, the age 
adjustments applied in our study are estimates. Complete 
records of gestational age were not available and patients 
under 3 months old were assumed to be neonates. In 
addition to possibly over-estimating the adjustments 
required for neonates, this also meant detailed 
adjustments could not be made for postnatal vial 
requirements. For children and teenagers, average daily 
vial requirements were extrapolated from standard 
paediatric weight-for-age reference ranges and not actual 
patient weight. Due to the preliminary nature of this work 
we did not perform any a priori sample size calculations, 
nor did we assess agreement as a function of time. While 
these are limitations of this study, they may be overcome in 
future studies; gestational and postnatal age are collected 
by Australian PICU’s and measured weights are now 
available for electronic extraction in the study hospital. Age 
adjustments may also be influenced by the ordering 
process if antibiotics were supplied and administered in 
separate months. Finally, the measures were not compared 
to actual days of use. Such validation would require a 
prospective observational study or access to electronic 
medication administration or prescribing data, which were 
neither feasible nor available. However, this work is an 
important initial exploration in an area in which there 
remains an unmet need and highlights the need to include 
detailed information on the local setting when reporting on 
antimicrobial use. Namely, pharmacy drug distribution 
systems and relevant infection control or medication 
handling policies. In addition, the principles applied in this 
study may be utilised for other injectable medications in 
hospitals with similarly limited pharmacy services, 
particularly those with a narrow dosage range.  
Further research is needed to assess whether agreement 
between estimated vial-based measures or selected 
antibiotic DDD and actual use are acceptable for local 
surveillance, national benchmarking programs and/or 
epidemiological studies. Initial studies should investigate 
drug distribution systems, presence of single vial policies, 
hospital formularies and medication dosage guidelines for 
similarities. Broad-spectrum agents associated with 
hospital acquired and resistant infections including, but not 
limited to carbapenems, vancomycin, linezolid and 
daptomycin should be prioritised. Consensus based 
methods may be required to reconcile discrepancies 
between prescribed doses and reference ranges used to 
define paediatric measures. 
 
CONCLUSIONS 
Paediatric antibiotic use reports generated from pharmacy 
information systems may not reflect actual administration 
because of the influence of variable vial size, patient age, 
pharmacy drug distribution systems and local medication 
handling and infection control policies. These factors 
should be assessed before inter-hospital comparisons are 
made. Agreement between the DDD and estimated daily 
vials and age-adjusted daily vials were superior to total 
recommended daily doses and unchanged by drug 
shortages in a PICU with a single vial policy. In this setting, a 
considerable number of antibiotics targeted by AMS 
programs may be reported in DDD when used for children 
and teenagers. 
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